College of Medicine
Camilly Pires de Mello, Ph.D., started working at the Molecular Virology laboratory in Brazil in 2008 where she studied different types of compounds and their activity against herpes simplex type 1 (HSV- 1). After Dr. Pires de Mello graduated from college with a major in biology, she started a master’s program in science and biotechnology at Universidade Federal Fluminense. As a master’s student, she continued her research with new antiviral agents to treat HSV-1, but focused more on their mechanism of action. As soon as she graduated she started her Ph.D. program. Her research project was to further study the toxicity of various inhibitors to determine whether or not there was an effect on latent infection of HSV-1.
In 2013, Dr. Pires de Mello was awarded with a scholarship from a Brazilian government funding institution (CNPq) to come to the United States and do part of her Ph.D. research at UF. After a year of work at UF, she returned to Brazil to finish her Ph.D. program. During her entire journey to achieve her doctoral degree, she attended regional, national and international meetings to present her research. She also published papers in recognized international journals such as Antiviral Therapy. After graduating and obtaining her Ph.D. in 2016, Dr. Pires de Mello accepted a post-doctoral associate position at the Institute for Therapeutic Innovation at UF. Her research is focused on mono- and combination therapies against RNA viruses such as Zika, Dengue, Chikungunya, Influenza and Hepatitis C virus using state-of-the-art in vitro pharmacodynamics infection model systems.